Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States.
暂无分享,去创建一个
K. Kalunian | M. Eaddy | M. Dall'Era | P. Mina-Osorio | N. Solomons | E. Farrelly | V. Birardi | A. Ogbonnaya | S. Randhawa | Eric Turowski
[1] B. Rovin,et al. Induction and maintenance therapy of lupus nephritis: an obituary. , 2021, Kidney international.
[2] E. Frangou,et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis , 2020, Annals of the Rheumatic Diseases.
[3] B. Rovin,et al. Update on Lupus Nephritis: Core Curriculum 2020. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[4] E. Morand,et al. Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus , 2020, Arthritis care & research.
[5] E. Lewis,et al. Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes , 2019, Arthritis & rheumatology.
[6] L. Magder,et al. Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis , 2018, The Journal of Rheumatology.
[7] C. Gordon,et al. The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project , 2017, Arthritis & rheumatology.
[8] C. Gordon,et al. The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program , 2017, Arthritis & rheumatology.
[9] E. Bonfá,et al. Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? , 2017, Lupus Science & Medicine.
[10] B. Rovin,et al. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. , 2016, Kidney international.
[11] Paul J. Hoover,et al. Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective. , 2016, Kidney international.
[12] Caroline Gordon,et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. , 2016, Rheumatology.
[13] D. D'cruz,et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis , 2015, Annals of the rheumatic diseases.
[14] B. Rovin,et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial , 2015, Lupus Science & Medicine.
[15] B. Rovin,et al. Predictors of Long‐Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro‐Lupus Nephritis Cohort , 2015, Arthritis & rheumatology.
[16] D. Furst,et al. Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population , 2013, Journal of medical economics.
[17] Caroline Gordon,et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis , 2012, Annals of the rheumatic diseases.
[18] L. Chibnik,et al. Identification and validation of lupus nephritis cases using administrative data , 2010, Lupus.
[19] P. Brunetta,et al. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database. , 2009, Clinical therapeutics.
[20] SUPPORTING TABLES,et al. KDIGO clinical practice guideline for the care of kidney transplant recipients. , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[21] R. Goetzel,et al. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population. , 2009, Arthritis and rheumatism.